TAAR1 and hyperprolactinemia: Though the MOA of ulotaront in the treatment of schizophrenia has not been fully elucidated, a growing body of evidence [32, 35] suggests that the efficacy of ulotaront is mediated through agonism at TAAR1 and serotonin 5-HT1A receptors. Via this novel mechanism, it is thought that ulotaront may provide a distinct risk/benefit profile notably lacking D2 antipsychotic class-related AEs (e.g., EPS, hyperprolactinemia, and adverse weight and metabolic effects).